HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese OTC Patch Manufacturer Feels Pain Of US FDA Import Alert, Warning

Executive Summary

FDA places Kangdi Medical Devices on import alert and warns it on GMP violations initially noted in 2016. FDA also notes in warning that the Chinese company’s two pain-relief patches are noncompliant with the external analgesics TFM.

You may also be interested in...

More GMP Warnings, Import Alerts For OTC Firms As US FDA Capped List Of Uninspected Facilities

Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.

Wild Child Netted Down Under In US FDA Initiative To Inspect All Drug Facilities

FDA says Wild Child, which provides products as a contract manufacturer and for private label sales, violated drug GMPs for products including sun care, lice treatment and acne lotion and attempted to avoid US testing standards by relying on Australian mandates.

FDA’s Record-Number GMP Warnings In FY 2019 Included First Of A Kind

Total GMP warnings in FY19 was 98, more than half to US firms. Warning to Dollar Tree “should serve as a reminder that although distributors may not be subject to CGMP requirement themselves, they are responsible for ensuring the drugs they distribute into interstate commerce are not adulterated,” says CDER compliance chief Donald Ashley.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts